Skip to main content
BTAI
NASDAQ Life Sciences

BioXcel的BXCL501在阿片类药物戒断研究的2期试验中显示出积极结果

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$1.99
Mkt Cap
$36.085M
52W Low
$1.17
52W High
$8.08
Market data snapshot near publication time

summarizeSummary

BioXcel Therapeutics宣布了一项由哥伦比亚大学领导的2期试验的积极顶线结果，该试验评估了BXCL501用于治疗阿片类药物戒断的效果。该研究表明，BXCL501表现出临床益处和有利的耐受性特征，适用于管理阿片类药物戒断症状。这对于该公司来说是一个高度重要的发展，因为积极的2期数据显著降低了资产风险，并扩大了BXCL501的潜在市场机会，BXCL501已经获得了用于治疗躁动的批准。对于微型生物技术公司来说，这样的临床进展是至关重要的催化剂，可以驱动大量投资者的兴趣和重新评估公司的估值。交易者将密切监视详细的数据展示和公司关于将BXCL501推进到这一新适应症的关键试验的战略计划。

在该公告发布时，BTAI的交易价格为$1.99，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3608.5万。 52周交易区间为$1.17至$8.08。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed BTAI - Latest Insights

BTAI
Apr 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
BioXcel Therapeutics Grants Warrants to Lenders, Potentially Diluting Shareholders by Over 5%
Sentiment: Negative
View Wiseek Article
BTAI
Apr 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
DoW-Funded Phase 2a Trial for BioXcel's BXCL501 in Acute Stress Reactions Begins Enrollment
Sentiment: Positive
View Wiseek Article
BTAI
Apr 01, 2026, 6:58 AM EDT
Filing Type: 8-K
Importance Score:
8
FDA Accepts sNDA for At-Home IGALMI® Use, Sets November PDUFA Date
Sentiment: Positive
View Wiseek Article
BTAI
Mar 27, 2026, 5:02 PM EDT
Filing Type: 10-K
Importance Score:
9
BioXcel Therapeutics Discloses Substantial Going Concern Doubt, Reports Increased Losses, and Details Debt Restructuring Amid Clinical Setbacks
Sentiment: Negative
View Wiseek Article
BTAI
Mar 27, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
9
BioXcel Therapeutics Reports Going Concern Doubt, Wider Net Loss, and Decreased IGALMI Revenue
Sentiment: Negative
View Wiseek Article
BTAI
Mar 27, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
BioXcel Therapeutics Beats Q4 Estimates with Narrower Loss, Higher Revenue
Sentiment: Positive
View Wiseek Article
BTAI
Mar 11, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
BioXcel Completes $7.8M Offering, Amends Warrants with Lower Exercise Price and Extended Term
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 11, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
BioXcel Therapeutics Closes $7.8M Registered Direct Offering and Amends Existing Warrants
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 11, 2026, 8:09 AM EDT
Filing Type: 424B5
Importance Score:
8
BioXcel Therapeutics Finalizes $7.3M Registered Direct Offering with Significant Dilution
Sentiment: Neutral
View Wiseek Article
BTAI
Mar 10, 2026, 2:36 PM EDT
Source: GlobeNewswire
Importance Score:
8
BioXcel Therapeutics Secures $8M Registered Direct Offering at Premium to Market Price
Sentiment: Neutral
View Wiseek Article